2025-02-25 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Performance Review

This report analyzes the performance of Eli Lilly and Co. (LLY), a leading pharmaceutical company, comparing its returns to the S&P 500 (VOO) and examining key financial metrics.

**1) Performance Comparison with S&P 500:**

LLY's cumulative return is significantly higher than the S&P 500's.

* **LLY Cumulative Return:** 643.29%
* **VOO (S&P 500) Cumulative Return:** 117.28%
* **Return Difference:** 526.01% (This represents the difference on the last day of the data period.  Note that the relative divergence of 83.5% indicates its position within the historical range of this difference, not a simple percentage outperformance.)


The provided alpha and beta analysis shows varying levels of outperformance (alpha) and market sensitivity (beta) across different time periods.  While alpha is generally positive, indicating outperformance,  the beta is relatively stable around 0.3, suggesting LLY's returns are less volatile than the overall market.  The substantial increase in market capitalization (Cap(B)) over the years also reflects growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 9.0% | 4.3% | -19.0% | 0.0 | 67.8 |
| 2016-2018  | 47.0% | 4.3% | 29.0% | 0.0 | 95.3 |
| 2017-2019  | 60.0% | 8.7% | 29.0% | 1.1 | 110.6 |
| 2018-2020  | 90.0% | 11.1% | 62.0% | 0.3 | 145.0 |
| 2019-2021  | 145.0% | 11.1% | 74.0% | 0.2 | 240.8 |
| 2020-2022  | 196.0% | 11.1% | 188.0% | 0.2 | 323.3 |
| 2021-2023  | 300.0% | 10.8% | 277.0% | 0.3 | 520.2 |
| 2022-2024  | 396.0% | 11.1% | 363.0% | 0.3 | 693.4 |
| 2023-2025  | 400.0% | 11.1% | 342.0% | 0.3 | 791.6 |


**2) Recent Price Movement:**

* **Closing Price:** $881.40
* **5-Day Moving Average:** $870.49
* **20-Day Moving Average:** $847.72
* **60-Day Moving Average:** $803.62

The price is above all three moving averages, suggesting an upward trend. The recent price change of $0.88 (0.88%) indicates a modest increase from the previous close.


**3) Technical Indicators and Expected Return:**

* **RSI:** 72.90 (Approaching overbought territory;  caution advised)
* **PPO:** 0.11 (Positive, suggesting upward momentum)
* **20-Day Relative Divergence Change:** +5.4% (Short-term upward trend)
* **Expected Return (2+ years):** 91.7% (Significant outperformance compared to the S&P 500 is anticipated for long-term investors.)


**4) Recent Earnings Analysis:**

The earnings data shows significant variability in EPS and revenue.  Note the unusual duplication of the October 30th, 2024 data point.  Further investigation into the data source is recommended to ensure accuracy.  More consistent data would allow for a more robust analysis of growth trends and seasonality.


| Date       | EPS   | Revenue       |
|------------|-------|----------------|
| 2024-10-30 | 1.08  | $11.44B        |
| 2024-08-08 | 3.29  | $11.30B        |
| 2024-04-30 | 2.49  | $8.77B         |
| 2023-11-02 | -0.06 | $9.50B         |
| 2024-10-30 | -0.06 | $9.50B         |


**5) Financial Information:**

Revenue shows consistent growth throughout the provided timeframe, with high profit margins consistently above 80%.  Equity has also increased, and ROE, while fluctuating, generally indicates strong profitability.  Further analysis of these metrics over a longer period would provide a more comprehensive understanding of the company's financial health and sustainability.

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $13.53B  | 82.24%        |
| 2024-09-30 | $11.44B  | 81.02%        |
| 2024-06-30 | $11.30B  | 80.80%        |
| 2024-03-31 | $8.77B   | 80.91%        |
| 2023-12-31 | $9.35B   | 80.88%        |

**Capital and Profitability:**

| Quarter | Equity    | ROE      |
|---------|-----------|----------|
| 2024-12-31 | $14.19B  | 31.07%   |
| 2024-09-30 | $14.24B  | 6.81%    |
| 2024-06-30 | $13.56B  | 21.88%   |
| 2024-03-31 | $12.81B  | 17.51%   |
| 2023-12-31 | $10.77B  | 20.33%   |


**6) Overall Analysis:**

LLY has demonstrated exceptional performance, significantly outperforming the S&P 500 over the measured period.  Positive PPO and the upward trend indicated by moving averages suggest continued upward momentum in the short term. However, the RSI nearing overbought territory warrants caution.  Long-term investors may find the high expected return compelling, but the variability in quarterly earnings warrants further scrutiny.  A thorough review of the data source to resolve inconsistencies and a longer-term analysis are recommended for a more complete assessment.  The high profit margins and generally strong financial indicators suggest a healthy company, but careful consideration of the high valuation relative to the market should be included in any investment decision.
